Titlebook: Antiviral Strategies; Hans-Georg Kräusslich,Ralf Bartenschlager Book 2009 Springer-Verlag Berlin Heidelberg 2009 Antiviral Drug.DNA.Drug R

languor

Inhibitors of Viral Entry,e cycles and, in the context of HIV treatment, contributes to the growing armamentarium of antivirals which, in multidrug combinations, can effectively inhibit viral replication and prevent disease progression.

反感

Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses,eic acid-based therapeutics. Antiviral RNAi approaches are highly effective in vitro and in animal models and are currently being tested in clinical trials. Here we give an overview of antiviral nucleic acid-based therapeutics. We focus on antisense and RNAi-based compounds that have been shown to be effective in animal model systems.

中世纪

尖

dowagers-hump

消耗

Maria A. Wimmer,Hans J. Scholl,Enrico Ferron grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those “other” targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.

天然热喷泉

Other Inhibitors of Viral Enzymes and Functions,n grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those “other” targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.

orient

Antiviral Strategies,ecome increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interf

Chagrin

无法取消

Viral Protease Inhibitors,velopment is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovi